WO2018086498A1 - Composition pharmaceutique et application de cette dernière - Google Patents

Composition pharmaceutique et application de cette dernière Download PDF

Info

Publication number
WO2018086498A1
WO2018086498A1 PCT/CN2017/109597 CN2017109597W WO2018086498A1 WO 2018086498 A1 WO2018086498 A1 WO 2018086498A1 CN 2017109597 W CN2017109597 W CN 2017109597W WO 2018086498 A1 WO2018086498 A1 WO 2018086498A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
hydrochloride
parts
composition according
add
Prior art date
Application number
PCT/CN2017/109597
Other languages
English (en)
Chinese (zh)
Inventor
叶茂
徐颖
Original Assignee
重庆羽贝海科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 重庆羽贝海科技有限公司 filed Critical 重庆羽贝海科技有限公司
Publication of WO2018086498A1 publication Critical patent/WO2018086498A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Definitions

  • the present invention relates to a pharmaceutical composition, and more particularly to a sedative pharmaceutical composition.
  • chloral hydrate oral preparation It is the most commonly used sedative for children before the clinic. Because of its very bitter taste, many children refuse to take it or cause vomiting after taking it. The risk of aspiration is increased and even life-threatening. In addition, hydrated chloral metabolites are active and sometimes cause wake delay; at the same time, the first-pass effect of the drug is obvious, the sedative effect is uncertain, often leading to sedation failure, and many children often need to repeatedly use drugs.
  • Midazolam oral agent the sedative effect is not good, the success rate is only 60-75%.
  • luminal sodium intramuscular injection the success rate of sedation is about 80%, but accompanied by painful stimulation, causing harm to the child.
  • Dexmedetomidine hydrochloride is a dextrorotatory isomer of medetomidine. It is a derivative of imidazole and is a highly selective ⁇ 2 receptor agonist. Its chemical name is (+)-4-(S). -[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole hydrochloride, which acts on the ⁇ 2 receptor in the cerebral nucleus of the brainstem and produces a good sedative effect.
  • the bioavailability of medetomidine is 81.8% (72.6–92.1%), so adults and children can have a significant sedative effect after nasal instillation of dexmedetomidine, and have no inhibitory effect on the respiratory center; /kg dexmedetomidine is sedated, it is easy to be awakened by external stimuli, the wake-up rate can reach about 50%, leading to sedation failure; a larger dose of dexmedetomidine hydrochloride (> 2ug / kg) nasal drops, can produce heartbeat Too slow.
  • Ketamine is an NMDA receptor antagonist with analgesic sedative and sympathetic stimulating effects, but generally it requires a large dose, which is likely to cause an increase in blood pressure and arousal during awakening.
  • a pharmaceutical composition comprising a pharmaceutically active ingredient consisting of dexmedetomidine hydrochloride and ketamine hydrochloride.
  • the pharmaceutical composition can produce a significant synergistic effect, and the pharmaceutical composition is used for various examinations with high success rate of sedation, and almost no arousal by external stimulation during the sedation of the drug, no Significant side effects.
  • the mass ratio of dexmedetomidine hydrochloride to ketamine hydrochloride is from 1 to 5:500 to 3,000.
  • the mass ratio of dexmedetomidine hydrochloride to ketamine hydrochloride in the pharmaceutical composition of the present invention is 2:1000.
  • the present invention also provides a sedative drug comprising the pharmaceutical composition of the present invention as provided above and a pharmaceutically acceptable adjuvant.
  • the sedative drug of the present invention may be an aerosol, a nasal spray, a powder, a sublingual tablet, an injection, an oral solution, an oral tablet, a capsule or the like.
  • the sedative drug provided by the present invention is a nasal spray.
  • a nasal spray for sedation which comprises the following raw materials of weight ratio, characterized in that: dexmedetomidine hydrochloride 0.002 ⁇ 0.01 parts, ketamine hydrochloride 1 ⁇ 5 parts, polyethylene glycol 400 0.01 ⁇ 0.05 a portion, 0.1 to 1.5 parts of sodium chloride, 0.03 to 0.16 parts of disodium edetate, 0.3 to 0.9 parts of benzyl alcohol, 0.02 to 0.18 parts of glycerin, and 0.01 to 3.9 parts of sodium hydrogencarbonate;
  • the sedative drug provided by the present invention is administered in an amount of 1.1 mg/kg per time.
  • the pharmaceutical composition of the invention has synergistic effect, especially for sedation before child examination, and the effect is particularly prominent, so that the child can complete various examinations safely and effectively; the sedation success rate is as high as 96% or more, and the medicine has quick onset and wake up.
  • the side effects are small, no obvious adverse reactions, heart rate, blood pressure, etc. are normal, there is no awakening during the recovery period, and the safety is high.
  • Figure 1 HE staining micrograph of rat brain tissue; 1: control group CA1; 2: control group CA3; 3: experimental group CA1; 4: experimental group CA3.
  • Figure 2 Nissl staining micrograph of rat brain tissue; 1: control group CA1; 2: control group CA3; 3: experimental group CA1; 4: experimental group CA3.
  • a sedative drug comprising dexmedetomidine hydrochloride and ketamine hydrochloride and a pharmaceutically acceptable adjuvant, which is prepared as a nasal spray, and is prepared as follows:
  • a sedative drug comprising dexmedetomidine hydrochloride and ketamine hydrochloride and a pharmaceutically acceptable excipient, which is prepared by the following steps:
  • the foreign matter will be inspected after the sterilization, and the qualified samples will be outsourced, fully inspected, and stored in the warehouse.
  • a sedative drug comprising dexmedetomidine hydrochloride and ketamine hydrochloride and a pharmaceutically acceptable adjuvant, which are prepared into tablets, which are obtained by the following steps:
  • Powdered sodium and starch are separately used WF-20B universal crusher (equipment manufacturer: Jiangyin Fuzhong Machinery Co., Ltd.
  • Tableting Adjust the TP-1.5T single punching machine (equipment manufacturer: Changzhou Wangqun Pharmaceutical Machinery Co., Ltd.), press the tablet, set the film to 0.3g/piece, pay attention to control the loading;
  • mice 30 mice, weighing 22-25 g, male and female, were randomly divided into 3 groups, namely the drug combination injection prepared in Example 2 (Specification: dexamethasone hydrochloride) Midea 0.1mg/ml, Ketamine hydrochloride 0.05g/ml, administered at 0.1ml/10g), dexmedetomidine hydrochloride injection (Specification: 2ml: 0.2mg, administered at 0.1ml/10g, source: Jiangsu Heng Rui Pharmaceutical Co., Ltd.), ketamine hydrochloride injection (specification: 2ml / 0.1g, administered dose of 0.1ml / 10g, source: Jiangsu Hengrui Pharmaceutical Co., Ltd.).
  • mice in each group were placed in a transparent small box, first adapted for 2 minutes, and then began to observe and record the walking and other activities of each group of mice. The number of cases was recorded for 10 minutes, and the number of activities before administration was obtained. Then, after administration according to the relevant dose, the mice were again placed in a transparent small box, and the same condition was first adapted for 2 minutes, and then each group of mice was observed and recorded. The number of walking and other activities, recorded for 10 minutes, calculate the spontaneous activity inhibition rate of each mouse, the formula is as follows:
  • Spontaneous activity inhibition rate 100% ⁇ (number of spontaneous activities of mice before administration - number of spontaneous activities of mice after administration) / number of spontaneous activities of mice before administration
  • Effectiveness 100% ⁇ effective inhibition of the number of mice / total number of mice
  • the inhibition rate ⁇ 50% is considered as effective inhibition.
  • heart rate and blood pressure should be monitored during the experiment, and the phenomenon of agitation during the recovery period should be observed.
  • the experimental results show that the inhibition rate and the effective rate of the pharmaceutical composition of the present invention are significantly higher than those of the control group.
  • Heart rate, blood pressure and recovery period The pharmaceutical composition of the present invention is superior to the control group.
  • the newborn rats were perfused with 4% PFA, and then the rats were decapitated and the brain tissue of the newborn rats was quickly separated. The brain tissue was removed and perfused with 4% PFA. After dehydration and paraffin embedding, paraffin sections were prepared. For HE staining and Nissl staining.
  • the paraffin section was dewaxed by xylene, and the gradient (100%, 95%, 80%, 70%) was hydrated with alcohol. After rinsing with distilled water, it was stained with hematoxylin for 10 min, washed with tap water for 1 min, and separated by 1% hydrochloric acid ethanol solution. The blue liquid returned to blue, rinsed with water, stained with 0.5% eosin alcohol for 1 min, dehydrated with ascending gradient alcohol (80%, 95%, 100%), transparent with xylene, and observed under the light microscope of neutral gum seal. Take photos with the CA3 area.
  • Paraffin sections were deparaffinized by xylene, preheated at 57 ° C for 1% toluidine blue for 60 min, washed with ddH 2 O for 3 times, differentiated with 95% ethanol, decolorized, and mirrored until the background was clear. Dehydrated ethanol and xylene were transparent. The CA1 and CA3 regions of the hippocampus of the rat brain were observed under a light microscope with a neutral gum seal and photographed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique, comprenant un principe actif pharmaceutique constitué de chlorhydrate de dexmédétomidine et de chlorhydrate de kétamine. La composition pharmaceutique de la présente invention présente un effet synergique, et l'effet est particulièrement important lorsqu'il est utilisé pour la sédation d'enfants avant un examen médical, de telle sorte que différents examens d'enfants malades peuvent être réalisés efficacement. La composition pharmaceutique a un taux de réussite de sédation jusqu'à 96 % ou plus, un début d'action rapide et une contrôlabilité de récupération élevée. De plus, la composition pharmaceutique présente un faible effet secondaire, ne conduit à aucun effet indésirable évident, et ne provoque aucune agitation d'émergence due à la fréquence cardiaque normale et à la pression sanguine, et présente par conséquent une sécurité élevée.
PCT/CN2017/109597 2016-11-08 2017-11-06 Composition pharmaceutique et application de cette dernière WO2018086498A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610980450.0 2016-11-08
CN201610980450.0A CN106727524A (zh) 2016-11-08 2016-11-08 一种药物组合物及其应用

Publications (1)

Publication Number Publication Date
WO2018086498A1 true WO2018086498A1 (fr) 2018-05-17

Family

ID=58972661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/109597 WO2018086498A1 (fr) 2016-11-08 2017-11-06 Composition pharmaceutique et application de cette dernière

Country Status (2)

Country Link
CN (1) CN106727524A (fr)
WO (1) WO2018086498A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110893186A (zh) * 2018-09-12 2020-03-20 宜昌人福药业有限责任公司 一种药物组合物及其制备方法和用途
US11478422B2 (en) 2018-06-27 2022-10-25 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11786508B2 (en) 2016-12-31 2023-10-17 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11890272B2 (en) 2019-07-19 2024-02-06 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11998529B2 (en) 2023-06-30 2024-06-04 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106727524A (zh) * 2016-11-08 2017-05-31 叶茂 一种药物组合物及其应用
CN109620802A (zh) * 2018-12-05 2019-04-16 杜皓 一种麻醉用鼻喷剂及其制备方法
CN112107544A (zh) * 2019-06-28 2020-12-22 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
CN114306218B (zh) * 2020-09-30 2023-11-10 四川普锐特药业有限公司 满足药学抑菌要求的经粘膜给药r-氯胺酮药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148673A1 (en) * 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
CN101553210A (zh) * 2006-09-20 2009-10-07 奈克斯特安全有限公司 经吸入输送药物的方法和系统
CN102920708B (zh) * 2012-11-12 2014-08-27 范宏刚 一种猫用复方麻醉剂及制备方法
CN106727524A (zh) * 2016-11-08 2017-05-31 叶茂 一种药物组合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148673A1 (en) * 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
CN101553210A (zh) * 2006-09-20 2009-10-07 奈克斯特安全有限公司 经吸入输送药物的方法和系统
CN102920708B (zh) * 2012-11-12 2014-08-27 范宏刚 一种猫用复方麻醉剂及制备方法
CN106727524A (zh) * 2016-11-08 2017-05-31 叶茂 一种药物组合物及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN, YONGXUE ET AL.: "The Exploration of Anesthesia Approach with Dexmedetomidine-Ketamine Combination", HEBEI MEDICAL JOURNAL, vol. 35, no. 18, 30 September 2013 (2013-09-30), pages 2738 - 2740 *
LI, ZHANJUN ET AL.: "Anesthetic Efficacy of Different Doses of Dexmedetomidine Combined with Ketamine in Pediatric Patients Undergoing Closure of Ventricular Septal Defect", CHINESE JOURNAL OF ANESTHESIOLOGY, vol. 34, no. 4, 30 April 2014 (2014-04-30), pages 402 - 404 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786508B2 (en) 2016-12-31 2023-10-17 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11931340B2 (en) 2016-12-31 2024-03-19 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11839604B2 (en) 2016-12-31 2023-12-12 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11806429B2 (en) 2018-06-27 2023-11-07 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11559484B2 (en) 2018-06-27 2023-01-24 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11517524B2 (en) 2018-06-27 2022-12-06 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11497711B2 (en) 2018-06-27 2022-11-15 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11478422B2 (en) 2018-06-27 2022-10-25 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
CN110893186A (zh) * 2018-09-12 2020-03-20 宜昌人福药业有限责任公司 一种药物组合物及其制备方法和用途
US11890272B2 (en) 2019-07-19 2024-02-06 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11998528B1 (en) 2023-03-23 2024-06-04 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11998529B2 (en) 2023-06-30 2024-06-04 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Also Published As

Publication number Publication date
CN106727524A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
WO2018086498A1 (fr) Composition pharmaceutique et application de cette dernière
CN101292969A (zh) 丁酸(酪酸)在制备治疗肛肠疾病药物中的应用
TWI654987B (zh) 用於治療睡眠失調之纈草根萃取物和薰衣草油的組合
CN103877005A (zh) 一种复方奥氮平皮下埋植缓释剂
CN1217721A (zh) 治疗或预防间质膀胱炎的方法
CN103356697A (zh) 一种干细胞制剂及其制备的口服液
CN107744571B (zh) 一种改善血管内皮功能障碍的药物组合物及其制备方法和用途
CN101757443A (zh) 一种治疗血友病的中药制剂
CN110123920A (zh) 一种用于治疗失眠症的口腔速溶膜剂及其制备方法
CN111588763B (zh) 血栓通脉药物、制备方法及含量测定方法
CN108014098A (zh) 一种托伐普坦速释微丸制剂、制备方法
CN105147709B (zh) 一种替诺福韦二吡呋酯或其药用盐的用途
CN107982268A (zh) 一种托伐普坦制剂及其应用
CN105935443A (zh) 一种治疗糖尿病性白内障的药物组合物
JP2011246478A (ja) テルカゲパントカリウムの固形投与製剤
CN102579356B (zh) 一种注射用盐酸戊乙奎醚粉针剂的制备方法
CN104814933A (zh) 栀子提取物冻干粉针剂及其制备方法
CN104546899A (zh) 一种含有奥美拉唑的口服固体药物组合物
CN110693882A (zh) 一种舌下用药物组合物
CN110101802A (zh) 一种治疗高血压的药物组合物
CN110833553A (zh) 吡唑并嘧啶衍生物在治疗Arthus反应的用途
CN102784101A (zh) 一种美他多辛注射剂及其制备方法
CN103385883B (zh) 一种含盐酸托烷司琼和果糖的药物组合物
CN113967220B (zh) 具有急性心梗疗效的药物活性组合物
CN106511394A (zh) 九香虫脂肪油提取物的新用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17869570

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17869570

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17869570

Country of ref document: EP

Kind code of ref document: A1